Wave Life Sciences Ltd.

Hello, and welcome to Wave Life Sciences' first quarter 2026 earnings call. We ask that you please hold all questions until the completion of the formal remarks, at which time you'll be given instructions for the question and answer session. Also, as a reminder, this conference call is being recorded today. I will now turn the call over to Kate Roush, Vice President of Corporate Affairs and Investor Relations.

Thank you, Operator, and good morning to everyone on the call. Earlier this morning, we issued a press release outlining our first quarter 2026 earnings update. Joining me today with prepared remarks are Dr. Paul Bono, President and Chief Executive Officer, Dr. Eric Engelson, Chief Scientific Officer, Dr. Chris Wright, Chief Medical Officer, and Kyle Moran, Chief Financial Officer. The press release issued this morning is available on the investor section of our website, www.wavelifesciences.com. Before we begin, I would like to remind you that discussions during this conference call will include forward-looking statements. These statements are subject to several risks and uncertainties that could cause our actual results to differ materially from those described in these forward-looking statements. The factors that could cause actual results to differ are discussed in the press release issued today and in our SEC filings. We undertake no obligation to update or revise any forward-looking statement for any reason. I'd now like to turn the call over to Paul.

Thanks, Kate. And good morning to everyone joining us on today's call. Coming into the year, we outlined our key priorities for 2026. Accelerating development of WVE007, our Inhibini GalNec siRNA program for obesity, and rapidly advancing our RNA editing portfolio led by WVE006 for AATD and followed by WVE008 for PMPLA3 liver disease. Today, I'm pleased to share an update on the significant progress we've made towards these goals. We are rapidly advancing 007, which has the potential to be transformational in the treatment of cardiometabolic diseases, including obesity. Using our best-in-class chemistry, O7 continues to demonstrate a highly differentiated profile. Clinical data, even in a phase one population, continues to demonstrate improvement in body composition with fat loss, importantly, visceral fat loss and muscle preservation, impressive durability with potential for once or twice a year dosing, and a clean safety profile. We're accelerating 007 to the next stages of development, where we have the opportunity to unlock its full potential across multiple treatment settings. beginning with our Phase 2A trial in participants with higher BMI and with and without diabetes. We are preparing to initiate our Phase 2A trial this quarter, as the FDA has recently accepted the multi-dose portion of Enlight. Closely following the initiation of our Phase 2A trial in higher BMI participants, we plan to initiate studies evaluating 007 in combination with incretins and maintenance post-cessation of incretin treatment. In RNA editing, we continue to lead the field with 006. Clinical data from our ongoing Restoration 2 trial has already demonstrated the potential for 006 to provide a much-needed novel therapeutic option to individuals living with AATD, including generating over 20 micromolar of AAT protein during an acute phase response. It's important to note that these acute phase responses are the drivers of lung damage in AATD. We look forward to highlighting these data during the ATS conference and hosting an investor webcast to share our monthly 400 milligram multiple dose, as well as single dose 600 milligram data. Having already achieved therapeutically relevant AAT restoration with our interim data, we are on track to receive regulatory feedback on a potential accelerated approval pathway in mid-2026. We're also building on our success in RNA editing to advance our next candidate, WVE008, towards the clinic this year, which has the potential to address the 9 million individuals living with PNPLA3 liver disease. Beyond our lead RNAi and RNA editing programs, we are continuing to push the boundaries of innovation through our bifunctional modality that allows us to both silence and or edit to treat diseases with a single construct in a single dose. We're also advancing a growing pipeline of new hepatic and extra hepatic candidates. With the substantial progress we've made, we believe we are well positioned and well capitalized to advance our pipeline of transformational therapies for patients. Now, I'd like to turn the call over to Eric, who will discuss how we are leveraging our proprietary chemistry and human genetic insights to advance WVE-006 for AATD and WVE-007 for obesity. Eric.